{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:37Z","timestamp":1788981577764,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01021-1","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:25:23Z","timestamp":1784784323000},"page":"505-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors Affecting Pharmacokinetics and Dosing Strategies of Polymyxin B in Multidrug-resistant Gram-negative Infected Patients with Renal Impairment: A Systematic Review with Expert Opinion"],"prefix":"10.1007","volume":"51","author":[{"given":"Asha K.","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ioana","family":"Onofrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu Ramachandra","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohil A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Prabhu","family":"Attur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mitwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvana","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayanarayana","family":"Kunhikatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surulivel","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-969X","authenticated-orcid":false,"given":"Girish","family":"Thunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"1021_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.955633","volume":"13","author":"R Nie","year":"2022","unstructured":"Nie R, Li D, Wang P, Yan G, Leng B. Polymyxin B in patients with renal impairment: is it necessary to adjust dose? Front Pharmacol. 2022;13:955633. https:\/\/doi.org\/10.3389\/fphar.2022.955633.","journal-title":"Front Pharmacol"},{"key":"1021_CR2","unstructured":"U.S. Food and drug administration. US food and drug administration. Polymyxin B [package insert] [Internet]. 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=b56f18c0-ef5e-4ed9-a5af-f79f3cd189b6&type=display"},{"key":"1021_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL, Forrest A, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"key":"1021_CR4","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57:524\u201331. https:\/\/doi.org\/10.1093\/cid\/cit334.","journal-title":"Clin Infect Dis"},{"key":"1021_CR5","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01337-16","volume":"61","author":"V Thamlikitkul","year":"2017","unstructured":"Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, et al. Dosing and pharmacokinetics of polymyxin B in patients with renal insufficiency. Antimicrob Agents Chemother. 2017;61:e01337-16. https:\/\/doi.org\/10.1128\/AAC.01337-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1021_CR6","doi-asserted-by":"publisher","first-page":"7000","DOI":"10.1128\/AAC.00844-15","volume":"59","author":"BC Nelson","year":"2015","unstructured":"Nelson BC, Eiras DP, Gomez-Simmonds A, Loo AS, Satlin MJ, Jenkins SG, et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother. 2015;59:7000\u20136. https:\/\/doi.org\/10.1128\/AAC.00844-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1021_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1086\/592577","volume":"47","author":"AP Zavascki","year":"2008","unstructured":"Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis. 2008;47:1298\u2013304. https:\/\/doi.org\/10.1086\/592577.","journal-title":"Clin Infect Dis"},{"key":"1021_CR8","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/cid\/cir137","volume":"52","author":"ALH Kwa","year":"2011","unstructured":"Kwa ALH, Abdelraouf K, Low JGH, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis. 2011;52:1280\u20131. https:\/\/doi.org\/10.1093\/cid\/cir137.","journal-title":"Clin Infect Dis"},{"key":"1021_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/cpt.981","volume":"104","author":"P Manchandani","year":"2018","unstructured":"Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, et al. Population pharmacokinetics of polymyxin B. Clin Pharmacol Ther. 2018;104:534\u20138. https:\/\/doi.org\/10.1002\/cpt.981.","journal-title":"Clin Pharmacol Ther"},{"key":"1021_CR10","doi-asserted-by":"publisher","unstructured":"Tuon FF, Rocha JL, Gasparetto J. Polymyxin B and colistin\u2014the economic burden of nephrotoxicity against multidrug resistant bacteria. Journal of Medical Economics. Taylor & Francis; 2019; 22(2): 158-162. https:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.1080\/13696998.2018.1552431.","DOI":"10.1080\/13696998.2018.1552431"},{"key":"1021_CR11","doi-asserted-by":"publisher","DOI":"10.1590\/s2175-97902020000119036","author":"B Ismail","year":"2021","unstructured":"Ismail B, Shafei MN, Harun A, Ali S, Omar M, Derisi ZZ. Inappropriate doses of intravenous polymyxin B after renal adjustment lead to treatment failure. Braz J Pharm Sci. 2021. https:\/\/doi.org\/10.1590\/s2175-97902020000119036.","journal-title":"Braz J Pharm Sci"},{"key":"1021_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease. Clin J Am Soc Nephrol. 2018;13:1085\u201395. https:\/\/doi.org\/10.2215\/CJN.00340118.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1021_CR13","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","volume":"37","author":"G Choi","year":"2009","unstructured":"Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268\u201382. https:\/\/doi.org\/10.1097\/CCM.0b013e3181aab3d0.","journal-title":"Crit Care Med"},{"key":"1021_CR14","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.3390\/microorganisms9071401","volume":"9","author":"P P\u00f3voa","year":"2021","unstructured":"P\u00f3voa P, Moniz P, Pereira JG, Coelho L. Optimizing antimicrobial drug dosing in critically Ill patients. Microorganisms. 2021;9:1401. https:\/\/doi.org\/10.3390\/microorganisms9071401.","journal-title":"Microorganisms."},{"key":"1021_CR15","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.cmi.2023.05.018","volume":"29","author":"PO Hanafin","year":"2023","unstructured":"Hanafin PO, Kwa A, Zavascki AP, Sandri AM, Scheetz MH, Kubin CJ, et al. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients. Clin Microbiol Infect. 2023;29:1174\u201381. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.018.","journal-title":"Clin Microbiol Infect"},{"key":"1021_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/jac\/dkad012","volume":"78","author":"M-Y Pi","year":"2023","unstructured":"Pi M-Y, Cai C-J, Zuo L-Y, Zheng J-T, Zhang M-L, Lin X-B, et al. Population pharmacokinetics and limited sampling strategies of polymyxin B in critically ill patients. J Antimicrob Chemother. 2023;78:792\u2013801. https:\/\/doi.org\/10.1093\/jac\/dkad012.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00228-022-03415-x","volume":"79","author":"YA Surovoy","year":"2023","unstructured":"Surovoy YA, Burkin MA, Galvidis IA, Sobolev MA, Rende OC, Tsarenko SV. Comparative polymyxin B pharmacokinetics in critically ill patients with renal insufficiency and in continuous veno-venous hemodialysis. Eur J Clin Pharmacol. 2023;79:79\u201387. https:\/\/doi.org\/10.1007\/s00228-022-03415-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"1021_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106214","volume":"175","author":"X Luo","year":"2022","unstructured":"Luo X, Zhang Y, Liang P, Zhu H, Li M, Ding X, et al. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with\/without continuous renal replacement therapy. Eur J Pharm Sci. 2022;175:106214. https:\/\/doi.org\/10.1016\/j.ejps.2022.106214.","journal-title":"Eur J Pharm Sci"},{"key":"1021_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106599","volume":"60","author":"P Wang","year":"2022","unstructured":"Wang P, Xing H, Zhang F, Liu S, Lu Y, Zhang X, et al. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration. Int J Antimicrob Agents. 2022;60:106599. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106599.","journal-title":"Int J Antimicrob Agents"},{"key":"1021_CR20","doi-asserted-by":"publisher","first-page":"e01900","DOI":"10.1128\/AAC.01900-20","volume":"65","author":"P Wang","year":"2021","unstructured":"Wang P, Zhang Q, Zhu Z, Pei H, Feng M, Sun T, et al. Comparing the population pharmacokinetics of and acute kidney injury due to polymyxin B in Chinese patients with or without renal insufficiency. Antimicrob Agents Chemother. 2021;65:e01900-e1920. https:\/\/doi.org\/10.1128\/AAC.01900-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1021_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.727170","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Deng Y, Zhu Z-Y, Liu Y-P, Xu P, Li X, et al. Population pharmacokinetics of polymyxin B and dosage optimization in renal transplant patients. Front Pharmacol. 2021;12:727170. https:\/\/doi.org\/10.3389\/fphar.2021.727170.","journal-title":"Front Pharmacol"},{"key":"1021_CR22","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1111\/bcp.14576","volume":"87","author":"X-B Yu","year":"2021","unstructured":"Yu X-B, Jiao Z, Zhang C-H, Dai Y, Zhou Z-Y, Han L, et al. Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. Br J Clin Pharmacol. 2021;87:1869\u201377. https:\/\/doi.org\/10.1111\/bcp.14576.","journal-title":"Br J Clin Pharmacol"},{"key":"1021_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics8010024","volume":"8","author":"RL Nation","year":"2019","unstructured":"Nation RL, Rigatto MHP, Falci DR, Zavascki AP. Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity. Antibiotics (Basel). 2019;8:24. https:\/\/doi.org\/10.3390\/antibiotics8010024.","journal-title":"Antibiotics (Basel)."},{"key":"1021_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975066","author":"Z Yu","year":"2022","unstructured":"Yu Z, Liu X, Du X, Chen H, Zhao F, Zhou Z, et al. Pharmacokinetics\/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae. Front Pharmacol Frontiers. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.975066.","journal-title":"Front Pharmacol. Frontiers."},{"key":"1021_CR25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.chest.2018.09.004","volume":"155","author":"S Tandukar","year":"2019","unstructured":"Tandukar S, Palevsky PM. Continuous renal replacement therapy. Chest. 2019;155:626\u201338. https:\/\/doi.org\/10.1016\/j.chest.2018.09.004.","journal-title":"Chest"},{"key":"1021_CR26","unstructured":"Rajan AK, Rashid M, Chandran VP, Shanbhag V, Thunga G. Pharmacokinetic parameters of polymyxins in kidney disease patients- A systematic review and meta-analysis [Internet]. PROSPERO2021. CRD42021294141. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42021294141. (Accessed on 7-06-2026]."},{"key":"1021_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1021_CR28","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s11096-022-01390-y","volume":"44","author":"ABE Soliman","year":"2022","unstructured":"Soliman ABE, Pawluk SA, Wilby KJ, Rachid O. The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies. Int J Clin Pharm. 2022;44:894. https:\/\/doi.org\/10.1007\/s11096-022-01390-y.","journal-title":"Int J Clin Pharm"},{"key":"1021_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/00498254.2023.2217265","volume":"53","author":"M Ajmal","year":"2023","unstructured":"Ajmal M, Zamir A, Rehman AU, Imran I, Saeed H, Majeed A, et al. Clinical pharmacokinetics of cefixime: a systematic review. Xenobiotica. 2023;53:149\u201362. https:\/\/doi.org\/10.1080\/00498254.2023.2217265.","journal-title":"Xenobiotica"},{"key":"1021_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/jac\/dkae003","volume":"79","author":"T Lai","year":"2024","unstructured":"Lai T, Yeo C-Y, Rockliff B, Stokes M, Kim HY, Marais BJ, et al. Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review. J Antimicrob Chemother. 2024;79:703\u201311. https:\/\/doi.org\/10.1093\/jac\/dkae003.","journal-title":"J Antimicrob Chemother"},{"key":"1021_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107099","volume":"63","author":"P Wang","year":"2024","unstructured":"Wang P, Liu S, Sun T, Yang J. Daily fluid intake as a novel covariate affecting the population pharmacokinetics of polymyxin B in patients with sepsis. Int J Antimicrob Agents. 2024;63:107099. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107099.","journal-title":"Int J Antimicrob Agents"},{"key":"1021_CR32","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/cc4903","volume":"10","author":"Z Ricci","year":"2006","unstructured":"Ricci Z, Ronco C, Bachetoni A, D\u2019amico G, Rossi S, Alessandri E, et al. Solute removal during continuous renal replacement therapy in critically ill patients: convection versus diffusion. Crit Care. 2006;10:R67. https:\/\/doi.org\/10.1186\/cc4903.","journal-title":"Crit Care"},{"key":"1021_CR33","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1128\/AAC.02445-15","volume":"60","author":"P Manchandani","year":"2016","unstructured":"Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS-L, Eriksen JL, et al. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2016;60:1029\u201334. https:\/\/doi.org\/10.1128\/AAC.02445-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"1021_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijantimicag.2015.11.007","volume":"47","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Falci DR, Lopes NT, Zavascki AP. Clinical features and mortality of patients on renal replacement therapy receiving polymyxin B. Int J Antimicrob Agents. 2016;47:146\u201350. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.11.007.","journal-title":"Int J Antimicrob Agents"},{"key":"1021_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/pharmacy8010018","volume":"8","author":"SM Jang","year":"2020","unstructured":"Jang SM, Infante S, Abdi PA. Drug Dosing Considerations in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Pharmacy (Basel). 2020;8:18. https:\/\/doi.org\/10.3390\/pharmacy8010018.","journal-title":"Pharmacy (Basel)."},{"key":"1021_CR36","first-page":"83","volume":"17","author":"N Fealy","year":"2015","unstructured":"Fealy N, Aitken L, du Toit E, Baldwin I. Continuous renal replacement therapy: current practice in Australian and New Zealand intensive care units. Crit Care Resusc. 2015;17:83\u201391.","journal-title":"Crit Care Resusc"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01021-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01021-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01021-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:22Z","timestamp":1788980182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01021-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01021-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest, financial or non-financial related to this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required, as this study is based on previously published data and does not involve a new human or animal participants.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}